Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study

NCT00873041 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-transfusion Dependent Thalassemia

Interventions

DRUG: deferasirox
DRUG: placebo

Sponsor

Novartis Pharmaceuticals